Notably, inhibitory SIGLECs, such as CD33, SIGLEC-5, 7, 9, and 10, are upregulated in tumor-infiltrating CD4 and CD8 T cells across various cancer types, contributing to the failure of T cell responses (Jiang et al., 2022). This evidence concerns the gene CD33 and neoplasm.